Parkinson's Disease and Exosomes and extracellular vesicles: what the trial registry contains

Why this is studied in Parkinson's Disease

Parkinson's involves loss of dopaminergic neurons in the substantia nigra, making it one of the few neurodegenerative conditions with a defined cell type to replace. Pluripotent-derived dopaminergic grafts are a serious, decades-long research programme with surgical delivery — categorically different from intravenous infusions marketed for Parkinson's.

What exosomes means in this table

Exosome and extracellular-vesicle products are cell-free: vesicles harvested from cultured cells and given without the cells themselves. They are attractive commercially because they avoid live-cell logistics, and they are regulatorily contested for the same reason — several regulators have issued explicit warnings about unapproved exosome products marketed for human use.

The numbers

Every figure below comes from one reproducible query (parkinson disease x exosome) run against ClinicalTrials.gov API v2 on 2026-08-29.

How mature is this evidence?

The evidence base is small and unfinished: 5 registered records with no later-phase work and 2 enrolling.

1 records are marked completed and 0 ended early (terminated, withdrawn or suspended): 0% of registrations did not run to plan.

Median planned enrolment is 120 participants (largest single study: 700). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.

Where the studies are

Country coverage runs to 5, but the distribution has a long tail behind Poland at about 20% of mentions.

Legal pathway differs by country — see where cell therapy is legal, by country.

Who runs them

Lead sponsors split roughly 3 academic or hospital against 2 commercial — a academic profile. Commercial sponsorship is not a red flag by itself, but it changes publication incentives.

• Biocells Medical — 1 record
• The Foundation for Orthopaedics and Regenerative Medicine — 1 record
• Fujian Medical University Union Hospital — 1 record
• Healing Hope International — 1 record
• University of Alabama at Birmingham — 1 record

Representative registered studies

Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.

What this page does and does not tell you

Treat this as a map of research activity. It tells you whether a claim has an evidence programme behind it — not whether the treatment helped anyone.

If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.

Frequently asked

How many exosomes studies for Parkinson's Disease are recruiting right now?

2 of 5 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.

Is exosomes an approved treatment for Parkinson's Disease?

Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 5 registered studies tell you research exists, not that a product cleared review.

How advanced is the research on exosomes for Parkinson's Disease?

0 of 5 records carry a Phase 3 or Phase 4 label and 1 are marked completed. Registrations run from 2013 to 2026.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.